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Two splice sites on the human papillomavirus type 16 (HPV-16) genome are used exclusively by
the late capsid protein L1 mRNAs: SD3632 and SA5639. These splice sites are suppressed in
mitotic cells. This study showed that serine/arginine-rich protein 30c (SRp30c), also named
SFRS9, activated both SD3632 and SA5639 and induced production of L1 mRNA. Activation of
HPV-16 L1 mRNA splicing by SRp30c required an intact arginine/serine-repeat (RS) domain of
SRp30c. In addition to this effect, SRp30c could enhance L1 mRNA production indirectly by
inhibiting the early 39-splice site SA3358, which competed with the late 39-splice site SA5639.
SRp30c bound directly to sequences downstream of SA3358, suggesting that SRp30c inhibited
the enhancer at SA3358 and caused a redirection of splicing to the late 39-splice site SA5639.
This inhibitory effect of SRp30c was independent of its RS domain. These results suggest that
SRp30c can activate HPV-16 L1 mRNA expression via a bimodal mechanism: directly by
stimulating splicing to late splice sites and indirectly by inhibiting competing early splice sites.
INTRODUCTION
Human papillomavirus type 16 (HPV-16) is the most
common high-risk HPV type in the human population
(Howley & Lowy, 2001; zur Hausen, 2002). Although the
vast majority of HPV-16 infections are cleared by the
immune system of the host, chronic infections with HPV-
16 cause more than 400 000 cases of cervical cancer globally
each year (Longworth & Laimins, 2004; zur Hausen, 2002).
HPV-16 persistence probably requires a successful delay in
the production of the immunogenic capsid proteins L1 and
L2 at early stages in the virus life cycle to avoid host
immune responses. The L1 and L2 capsid proteins of HPV-
16 are normally expressed in terminally differentiated cells
in the upper layers of the mucosal epithelium (Doorbar,
2005; Longworth & Laimins, 2004). In chronic HPV-16
infections that deteriorate to anogenital cancer, L1 and L2
genes are efficiently shut down. Cervical cancer cells do not
express L1 or L2 protein, suggesting that inhibition of late
gene expression is a prerequisite for progression to cervical
cancer.
HPV late gene expression is regulated at least in part at the
level of RNA processing, and several reports have described
regulatory elements on late HPV mRNAs (Graham, 2008;
Schwartz, 2008; Zheng & Baker, 2006). These HPV RNA
elements control RNA processing such as viral mRNA
stability, splicing and translation. The late 39-untranslated
region (39UTR) has been identified as the location of RNA
regulatory elements in many HPV types, including HPV-16
(Graham, 2008; Zhao et al., 2007). RNA regulatory
elements have also been identified in the L1 and L2
protein-encoding regions of HPV-16 (Collier et al., 1998,
2002; Oberg et al., 2003). Reports also suggest that the
control of late gene expression extends to regulatory
elements in the early region of HPV-16, and polyadenyla-
tion elements at the early poly(A) signal pAE may influence
late gene expression (Zhao et al., 2005). The identification
of host cellular factors binding to these regulatory
sequences would help to resolve the mechanism of HPV-
16 late gene suppression in undifferentiated cells, including
cancer cells. The following factors have been shown to bind
to the HPV-16 and/or HPV-31 late 39UTR: HuR, U2 small
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nuclear ribonucleoprotein auxiliary factor 65 kDa subunit
(U2AF65), cleavage stimulation factor-64 (CstF-64), altern-
ative splicing factor/splicing factor 2 (ASF/SF2) and CUG-
binding protein (Cumming et al., 2002; Goraczniak &
Gunderson, 2008; Koffa et al., 2000; McPhillips et al.,
2004), whilst heterogeneous nuclear ribonucleoprotein
(hnRNP) C1/C2, HuR and poly(A)-binding protein
(PABP) bind to the late 39UTR of HPV-1 (Sokolowski &
Schwartz, 2001; Sokolowski et al., 1997, 1999). hnRNP C1/
C2, polypyrimidine tract binding-protein (PTB), CstF-64
and human Fip-1 have been shown to bind to a U-rich
region of the early 39UTR of HPV-16, a sequence that
enhances recognition of the early poly(A) signal pAE (Zhao
et al., 2005). The hnRNP A1 protein was shown to bind to
splicing silencers in the HPV-16 L1-encoding region (Zhao
et al., 2004), whilst hnRNP E, hnRNP K and hnRNP H
bind to the coding region of HPV-16 L2 (Collier et al.,
1998; Oberg et al., 2005). The binding sites for hnRNP H
coincide with downstream RNA elements that stimulate
HPV-16 early polyadenylation (Oberg et al., 2005). In
HPV-31, the corresponding RNA sequence interacts with
CstF-64 (Terhune et al., 2001).
Proteins that can induce HPV-16 late gene expression from
subgenomic HPV-16 expression plasmids have been
identified recently (Somberg & Schwartz, 2010; Somberg
et al., 2008, 2009). PTB was found to induce production of
the partially spliced L2 mRNA, suggesting that HPV-16
polyadenylation and/or splicing was targeted by PTB
(Somberg et al., 2008). In addition to PTB, the multi-
functional adenovirus E4orf4 protein induced production
of HPV-16 L1 mRNA (Somberg et al., 2009). As E4orf4
interacts with cellular serine/arginine-rich (SR) proteins (in
particular ASF/SF2) (Kanopka et al., 1996, 1998), these
results indicated that SR proteins regulate HPV-16 L1
mRNA splicing. We have shown previously that ASF/SF2
regulates HPV-16 mRNA splicing (Somberg & Schwartz,
2010), and Jia et al. (2009) showed that bovine papillo-
mavirus type 1 and HPV-16 splicing is regulated by SRp20.
In the case of HPV-16, one may therefore speculate that
splicing of the late L1 mRNA is absent in mitotic cells or
cervical cancer cells due to suboptimal levels of one or
more of the SR proteins (Schwartz, 2008).
RESULTS
SRp30c activates HPV-16 late mRNA splicing and
induces production of spliced L1 mRNA
In order to identify cellular factors that regulate HPV-16
late mRNA splicing, we co-transfected subgenomic HPV-
16 plasmid pBEL (Fig. 1a) with cDNAs expressing the SR
proteins SRp20, SRp30c, SC35, ASF/SF2, SRp40, SRp55 or
SRp75. The expression of SR proteins or PTB from the
plasmids used here has been demonstrated previously by
our group (PTB: Somberg et al., 2008; ASF/SF2: Somberg
& Schwartz, 2010; SRp40, SRp55 and SRp75: Tranell et al.,
2010). Production of SRp20 and SC35 is shown in Fig. 1(b,
lower panels). pBEL encoded viral early and late genes after
a human cytomegalovirus (CMV) immediate-early pro-
moter (Fig. 1a), but primarily produced the early E4
mRNA upon transfection of HeLa cells, as described
previously (Rush et al., 2005; Somberg & Schwartz, 2010;
Somberg et al., 2008, 2009; Zhao et al., 2004, 2005). HPV-
16 late L1 and L2 mRNAs were undetectable (Fig. 1b). This
is due to the efficient use of the early splice site SA3358 and
early poly(A) signal pAE (Rush et al., 2005; Somberg &
Schwartz, 2010; Zhao et al., 2005) and to suppression of the
late splice sites SD3632 and SA5639 (Fig. 1a) (Somberg &
Schwartz, 2010; Zhao et al., 2005). pBEL was co-transfected
with 1 mg each of plasmids expressing the various SR
proteins indicated in Fig. 1(b). Cytoplasmic RNA was
extracted and subjected to Northern blotting with an L1
probe (Fig. 1a). The results revealed that overexpression of
SRp30c induced late gene expression, primarily L1/L1i
mRNA (where L1i mRNA represents a ‘mutation-induced’
late message spliced from the position 880 59-splice site
directly to the position 5639 39-splice site), but not L2
mRNA (Fig. 1b). None of the other SR proteins induced
HPV-16 late gene expression (Fig. 1b). In addition, SR
protein 9G8, a splicing regulatory protein, failed to induce
HPV-16 late gene expression under these conditions (data
not shown). The induction of spliced L1 mRNA by SRp30c
is in contrast to the induction of partially spliced L2 mRNA
by PTB (hnRNP I) (Fig. 1b), as reported previously
(Somberg et al., 2008). Transfection of pBEL with serially
diluted SRp30c plasmid revealed that SRp30c induced L1
mRNA splicing in a dose-dependent manner (Fig. 1c). A
Western blot showed the levels of overexpression of
SRp30c in HeLa cells (Fig. 1d). We also transfected pBEL
with SRp30c in other cell lines such as 293T cells and C33A
with similar results (data not shown). Our results indicated
that overexpression of SRp30c activates splicing from
either SD3632 or SA5639, or both. We concluded that
SRp30c is an activator of HPV-16 late L1 mRNA splicing.
SRp30c inhibits splicing to early splice site
SA3358, thereby redirecting splicing to late splice
site SA5639
Two different L1 mRNAs are detected by the L1 probe, the
L1 and L1i mRNAs (Fig. 1a). These two mRNAs are not
easily separated by Northern blotting. To determine
whether SRp30c induced L1 or L1i mRNA, we analysed
RNA extracted from HeLa cells transfected with pBEL and
a serial dilution of SRp30c plasmid by RT-PCR. The results
revealed that low levels of SRp30c overexpression primarily
induced splicing of late mRNAs of the L1 type, whereas
higher levels of SRp30c overexpression induced late
mRNAs of the L1i type (Fig. 2a, b). These results confirmed
that SRp30c could overcome suppression of late splice site
SD3632 and/or SA5639. This production of L1i mRNAs at
high concentrations of transfected SRp30c plasmid sug-
gested that SRp30c induced L1 mRNA production by
another mechanism. The results suggested that SRp30c also
caused skipping of the exon between SA3358 and SD3632
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in the E4-encoding region of HPV-16 (Fig. 2a, b). To
confirm these results, the same RNA samples were
subjected to Northern blotting and analysed with a probe
for E4 mRNAs (Fig. 2c). Low levels of SRp30c marginally
affected early E4 mRNAs, and induced expression of L1
mRNA (Fig. 2c). These L1 mRNAs were of the L1 type
containing the central exon between SA3358 and SD3632,
as they were detected by the E4 probe. In contrast, higher
levels of SRp30c reduced levels of both E4 and L1 mRNAs
(Fig. 2c), whilst at the same time shifting expression to L1i
mRNAs. Hybridization of the same filter to an L1 probe,
which detects both L1 and L1i mRNAs, revealed that high
levels of SRp30c inhibited E4 and L1 mRNA production
but induced high levels of L1i mRNAs, which were detected
by the L1 probe (Fig. 2d) but not by the E4 probe (Fig. 2c).
Taken together, these results indicated that SRp30c
induced HPV-16 late gene expression by activation of late
splice sites and suppression of early splice sites, i.e. SA3358.
To confirm that this also occurred in the absence of the late
genes, serially diluted SRp30c was co-transfected with
pBearly (Fig. 2a), which lacks the late region of pBEL, but
contains the early splice sites SD880 and SA3358 that are
also present in pBEL. Northern blotting revealed that low
levels of SRp30c had little or no effect on E4 mRNAs (Fig.
2c), whereas high levels of SRp30c inhibited production of
early E4 mRNAs that were spliced to SA3358 (Fig. 2c).
These results indicated that SRp30c inhibited SA3358. In
addition, we transfected serially diluted SRp30c (0.125–
1.0 mg) with plasmid pBELM (Fig. 2a), in which the
splicing silencers at SA5639 had been inactivated. SRp30c
induced L1 mRNA production from this plasmid in a
manner similar to the induction of L1 from pBEL (low
levels of SRp30c induced primarily L1 mRNAs, whereas
high levels of SRp30c induced L1i mRNAs) (Fig. 2d and
data not shown). Taken together, these results demon-
strated that SRp30c induces HPV-16 late gene expression
by activating SA5639 and/or SD3632 to produce spliced L1
mRNAs, and by inhibiting early splice site SA3358 to
produce L1i mRNA by an exon-skipping mechanism.
To demonstrate further that the exon-skipping mechanism
was specific for SRp30c, we compared the effects of SRp30c
and adenovirus E4orf4 (AdE4orf4) on L1 mRNA produc-
tion. In contrast to SRp30c, AdE4orf4 induced primarily L1
mRNA and not L1i mRNA (Fig. 2e), as reported previously
(Somberg et al., 2009). This was confirmed by RT-PCR
(Fig. 2b). These results indicated that AdE4orf4 solely
induced late mRNA splicing from SD3632 to SA5639,
which confirmed our previously published results on
AdE4orf4 (Somberg et al., 2009). Although the same
splicing event could be activated by SRp30c, SRp30c also
inhibited splicing to SA3358 at high concentrations,
thereby indirectly inducing splicing directly from SD880
to SA5639. Quantitative PCR using SYBR Green on the
same cDNA samples revealed that overexpression of
SRp30c (0.125 mg) caused a 4.1-fold reduction in cycle
threshold value. Quantification of the L1 and L1i peaks
demonstrated that the L1i peak was 49 % of the L1+L1i
Fig. 1. (a) Schematic representation of the HPV-16 genome and
subgenomic HPV-16 expression plasmid pBEL (Zhao et al.,
2004). The early and late viral promoters p97 and p670 are
indicated. Numbers indicate nucleotide positions of 59-splice sites
(filled ovals), 39-splice sites (open ovals) or the early and late
poly(A) signals pAE and pAL, respectively. A subset of mRNAs
that may be produced by pBEL are indicated (Baker & Calef,
1997). The position of the L1 probe is shown. CMV, Human
cytomegalovirus promoter; LCR, long control region. (b) Upper
panel: Northern blot of cytoplasmic RNA extracted from HeLa cells
transfected with pBEL in the absence or presence of plasmids
expressing SRp20, SRp30c, SC35, ASF/SF2, SRp40, SRp55,
SRp75 or PTB and probed with the L1 probe. The positions of the
L2 and L1/L1i mRNAs, and 28S and 18S rRNAs are indicated.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
detected as a loading control. Lower panel: Western blots
demonstrating the production of SC35 and SRp20 from expres-
sion plasmids. (c) Northern blot of cytoplasmic RNA extracted from
HeLa cells transfected with pBEL and a 2-fold serial dilution of
SRp30c expression plasmid, starting at 4 mg, probed with the L1
probe. GAPDH was detected as a loading control. (d) Western
blot demonstrating overexpression of SRp30c in HeLa cells, using
anti-SRp30c antibody N-13 or anti-actin antibody I-19 as a
loading control (Santa Cruz Biotechnology).
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mRNAs at low levels of SRp30c (0.125 mg), whilst the L1i
peak shifted to 71 % of the L1+L1i mRNAs in the presence
of high levels of SRp30c (1 mg). Co-transfection of pBELM
with both SRp30c and AdE4orf4 resulted in high levels of
L1i (Fig. 2e), which was expected, as SRp30c would also
inhibit SA3358 in the presence of E4orf4. We concluded
that SRp30c induces production of both L1 and L1i
mRNA.
These results suggested that SRp30c binds directly to the
HPV-16 sequence between SA3358 and SD3632. To test
whether SRp30c interacts physically with this sequence, we
performed UV cross-linking of radiolabelled HPV-16 RNA
(nt 3407–3627) to glutathione S-transferase (GST)-fused
SRp30c (Fig. 3a). A Coomassie blue-stained acrylamide gel
demonstrated the purified GST–SRp30c (Fig. 3b). Whilst
the recombinant GST–SRp30c was cross-linked efficiently
Fig. 2. (a) Schematic representation of the subgenomic HPV-16 expression plasmids pBEL, pBELM and pBearly (Zhao et al.,
2004, 2005). Mut indicates a number of nucleotide substitutions that inactivated splicing silencers downstream of SA5639 in
plasmid pBELM (Zhao et al., 2004). Numbers indicate nucleotide positions of 59-splice sites (filled ovals), 39-splice sites (open
ovals) or the early and late poly(A) signals pAE and pAL, respectively. A subset of mRNAs that may be produced by the
plasmids is indicated. The positions of the E4 and L1 probes and RT-PCR primers 757s and L1A are shown. (b) RT-PCR with
primers 757s and L1A on cDNA of cytoplasmic RNA extracted from HeLa cells transfected with the indicated plasmids. pBEL
was transfected with a twofold serial dilution of SRp30c expression plasmid, starting at 4 mg. GAPDH was amplified from the
same cDNAs. PCR products representing mRNAs are indicated. M, Molecular size markers (bp). (c–e) Northern blots of
cytoplasmic RNA extracted from HeLa cells transfected with pBEL, pBELM or pBearly in the absence or presence of plasmids
expressing SRp30c or E4orf4. SRp30c expression plasmid was twofold serially diluted prior to transfection, starting at 4 mg.
HPV-16 mRNAs detected by the E4 or L1 probe are indicated, and the positions of the 28S and 18S rRNAs are indicated.
Actin was detected as a loading control.
M. Somberg and others
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to the HPV-16 RNA sequence, GST alone was not (Fig. 3c).
The interaction between the HPV-16 RNA and SRp30c was
sequence-specific, as a 4-fold excess of unlabelled HPV-16
RNA competed well with the probe for SRp30c, whilst little
or no competition was observed using a 20-fold excess of
unlabelled HPV-1 M5 RNA (Fig. 3d). We concluded the
SRp30c binds directly to the HPV-16 sequence between
SA3358 and SD3632. We cannot exclude the possibility
that SRp30c binds to other positions in the HPV-16
genome.
SRp30c induces exon skipping by interfering with
splicing enhancers downstream of SA3358 in an
RS domain-independent manner
Our results demonstrated that wild-type (WT) SRp30c
displayed properties similar to those of a trans-dominant
ASF/SF2 protein (Somberg & Schwartz, 2010), i.e. it
competed with WT ASF/SF2 for binding to the splicing
enhancer downstream of SA3358, thereby inhibiting SA3358
and redirecting splicing to SA5639. This trans-dominant
ASF/SF2 mutant, named ASFDRS, has been shown
previously to inhibit splicing to SA3358 (Somberg &
Schwartz, 2010). If induction of L1i mRNA by SRp30c
was the result of competition with ASF/SF2 for binding
to the splicing enhancer downstream of SA3358, an
SRp30c mutant lacking the RS domain should also be
able to induce L1i mRNA production. This prompted us
to investigate the effect on HPV-16 late gene expression
of an SRp30c mutant that lacked the RS domain
(SRp30cDRS). Transfection of SRp30cDRS with pBELM
followed by analysis of L1 mRNA production revealed
that both WT SRp30c and SRp30cDRS induced produc-
tion of L1/L1i mRNA to similar levels (Fig. 4a).
Interestingly, SRp30c and SRp30cDRS induced similar
levels of L1i mRNA from pBELM, demonstrating that the
major L1i-inducing mechanism of both SRp30c and
SRp30cDRS was inhibition of SA3358. RT-PCR analysis
confirmed that both proteins induced HPV-16 late
mRNAs of the L1i type, indicative of skipping of the
internal exon SA3358–SD3632 in the E4-encoding region
(Fig. 4b). Similar results were obtained with ASFDRS
Fig. 3. (a) Schematic representation of the HPV-16 genome and position of the in vitro-synthesized HPV-16 RNA probe used
for UV cross-linking. (b) Coomassie blue-stained acrylamide gel with purified recombinant GST or GST–SRp30c protein. BSA
(2 and 1 mg, as indicated) was also loaded on the gel. (c) UV cross-linking of 2 mg GST or twofold serially diluted GST–
SRp30c (starting at 2 mg) to the in vitro-synthesized, radiolabelled HPV-16 RNA probe shown in (a). (d) UV cross-linking of
GST or GST–SRp30c to the radiolabelled HPV-16 RNA probe shown in (a) in the presence of a fourfold excess of cold HPV-
16 RNA probe (wt) or a 20-fold excess of mutant HPV-1 AU-rich RNA element (M5).
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(Fig. 4a, b), as reported previously (Somberg & Schwartz,
2010), whereas overexpression of WT ASF/SF2 at these
levels showed no detectable effect on L1 mRNA
expression, as expected (Fig. 4a). As an additional
control, we monitored the effect of SRp55 on HPV-16
late gene expression. The results revealed that neither
SRp55 nor SRp55DRS affected HPV-16 late gene ex-
pression (Fig. 4a). Overexpression of ASF/SF2, SRp30c
and SRp55 was monitored by Western blotting (Fig. 4d).
Collectively, our results demonstrated that SRp30c could
activate L1i mRNA production by an exon-skipping
mechanism.
Induction of HPV-16 L1 mRNA splicing from
SD3632 to SA5639 requires the RS domain of
SRp30c
Although we had confirmed that SRp30c could induce L1i
production from pBELM by an exon-skipping mechanism,
results on the WT pBEL plasmid shown in Fig. 2
demonstrated clearly that SRp30c also activated splicing
from either late splice site SA5639 or SD3632, or both, as
L1 mRNAs were produced from pBEL in the presence of
exogenous SRp30c. These results suggested direct activa-
tion of one or both HPV-16 late splice sites. Next, we
Fig. 4. (a) Northern blot of cytoplasmic RNA extracted from HeLa cells transfected with pBELM in the absence or presence of
plasmids expressing SRp30c, SRp30cDRS, ASF/SF2, ASFDRS, SRp55 or SRp55DRS. Blots were probed with the L1 or
GAPDH probe. The L1/L1i and GAPDH mRNAs and the 28S and 18S rRNAs are indicated. (b) RT-PCR with primers 757s and
L1A (see Fig. 2a) on cDNA synthesized from HeLa cells transfected with pBELM and the indicated SR protein expression
plasmids. cDNAs representing L1 or L1i mRNAs are indicated. M, Molecular size markers (bp). (c) Northern blots of cytoplasmic
RNA extracted from HeLa cells transfected with pBEL, pBELM, pBSplice and pBSpliceM in the absence or presence of
SRp30cDRS. Blots were probed with the L1 or E4 probe. For positions of probes, see Fig. 2(a). E4, L1, L1i and GAPDH
mRNAs are indicated in the figure. (d) Western blots with antibody 1H4 specific for various SR proteins (Santa Cruz
Biotechnology) or antiserum #65 (Somberg & Schwartz, 2010) demonstrating overexpression of various SR proteins.
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investigated whether the RS domain of SRp30c was
required for activation of splicing from WT plasmid
pBEL. The results revealed that SRp30cDRS could not
induce L1 mRNA production from pBEL, in which SA5639
was suppressed by downstream splicing silencers in the L1-
encoding region (Fig. 4c), whereas high levels of L1 mRNA
were induced from pBELM, in which the splicing silencers
had been inactivated, as expected (Fig. 4c). However,
SRp30cDRS did inhibit expression of E4 mRNA from both
pBEL and pBELM (Fig. 4c). These results demonstrated
that SRp30cDRS could inhibit SA3358, but, in contrast to
WT SRp30c, it could not activate splicing to WT SA5639 in
pBEL. We concluded that activation of late splice sites
SD3632 and/or SA5639 by SRp30c required an intact RS
domain, whereas inhibition of SA3358 did not.
To demonstrate that WT SRp30c could activate splice sites
SD3632 and/or SA5639, and did not solely induce L1
mRNA production indirectly by inhibiting SA3358, we
investigated the effect of SRp30c on HPV-16 plasmids
pBSplice and pBSpliceM (Fig. 5a) (Somberg et al., 2008).
These plasmids are derived from pBEL and pBELM (Fig.
2a), respectively, and both contain a large deletion in the
early region that removes all early splice sites including
SA3358, whereas the two late HPV-16 splice sites SD3632
and SA5639 are intact (Fig. 5a). mRNAs that could
potentially be produced from pBSplice and pBSpliceM are
shown below the schematic representations of the
plasmids in Fig. 5(a). We have shown previously that
none of these plasmids expresses detectable levels of L1
mRNAs upon transfection of HeLa cells. This is
presumably an effect of the efficient suppression of splice
sites SD3632 and SA5639 in HeLa cells. However, co-
transfection of pBSplice with SRp30c activated splicing
from SD3632 to SA5639 to produce spliced L1 mRNAs
(Fig. 5b). These results clearly demonstrated that SRp30c
alleviates inhibition of SD3632 and/or SA5639. In
addition, SRp30c activated splicing from pBSpliceM
(Fig. 5a), in which splicing silencers at SA5639 had been
inactivated, demonstrating that SRp30c activated splicing
from SD3632 (Fig. 5b). In contrast to WT SRp30c, mutant
SRp30cDRS did not induce L1 mRNA expression from
pBSplice (Fig. 4c) and only low levels of L1 mRNAs were
produced from pBSpliceM in the presence of SRp30cDRS
(Fig. 4c). These results supported the idea that
SRp30cDRS induced L1 mRNA expression solely by
inhibiting SA3358, thereby redirecting splicing to
SA5639. We concluded that activation of splicing between
SD3632 and SA5639 by SRp30c required an intact RS
domain and that WT SRp30c could both activate splicing
from SD3632 and inhibit splicing to SA3358.
SRp30c interferes with splicing regulatory
sequences at SD3632
To investigate whether SRp30c could activate splicing from
pBspliceM when splicing inhibitory sequences at SD3632
had been deleted, we overexpressed SRp30c with a number
of HPV-16 deletion mutants (Fig. 5a). SRp30c did not have
a major effect on L1 mRNA production if sequences
upstream (pMT1SD) or downstream (pBSpM3703–4530)
of SD3632 were deleted and suppression of splicing at
SD3632 was alleviated (Fig. 5c, d). In contrast, plasmids
with smaller deletions downstream of SD3632 as in pMT3,
or deletions in L2 as in pBSpM4288–4530 (Fig. 5a), which
did not activate L1 (Fig. 5b), responded well to SRp30c
(Fig. 5c, d). Taken together, these results indicated that
SRp30c activates splicing of late splice site SD3632 by
interfering with splicing inhibitory RNA elements in an RS
domain-dependent manner.
Evidence that SRp30c overcomes suppression of
both HPV-16 late splice sites, SD3632 and SA5639
Our results demonstrated that SRp30c activated splicing
from the late 59-splice site SD3632. We also wished to
determine whether SRp30c acted directly on the late 39-
splice site SA5639. To test the effect of SRp30c on each
splice site individually, we optimized SD3632 in the
context of WT SA5639, and vice versa, in the background
of plasmid pBEL (Fig. 6a). SD3632 was optimized either
by improving the complementarity of SD3632 to U1
small nuclear ribonucleoprotein (U1snRNP) up to
100 %, or by introducing the T9 deletion upstream of
SD3632, which has been shown to activate SD3632 (Rush
et al., 2005; Somberg et al., 2008), resulting in plasmids
pOPSD and pBELT9, respectively (Fig. 6a). If SRp30c
activated only SD3632 and not SA5639, these plasmids
should not respond to SRp30c. However, co-transfection
of SRp30c with either pOPSD or pBELT9 resulted in
induction of L1 mRNA production (Fig. 6b). RT-PCR
analysis revealed that the induced mRNAs were primarily
L1 mRNAs (Fig. 6c) and not L1i mRNA, demonstrating
that SRp30c induced splicing from the optimized SD3632
to WT SA5639. Interestingly, SRp30c induced both L1i
and L1 mRNA from pBEL, confirming that both SD3632
and SA5639 were activated by SRp30c (Fig. 6c). The lack
of L1i mRNA production from pBELT9 and pOPSD is
probably the result of a more efficient exon definition of
the SA3358–SD3632 exon as a result of the improved
SD3632 in these plasmids. As expected, SRp30c also
induced L1 mRNA production from pBELM in which
splicing silencers at SA5639 had been inactivated (Fig.
6b), as also seen in Fig. 2(d, e) and Fig. 4(a–c). In
contrast, optimization of both SD3632 and SA5639, as in
plasmids pT9 and pOPSDM, resulted in constitutive, high-
level production primarily of L1 mRNAs (Fig. 6b, c). These
L1 mRNA levels were not increased further by SRp30c, as
expected (Fig. 6b, c). Therefore, SRp30c could activate
splicing from both late splice sites, SD3632 and SA5639, on
the HPV-16 genome. Taken together, our results established
firmly that SRp30c induced L1 mRNA production by
activating splicing from the two late splice sites, SD3632 and
SA5639, and induced L1i mRNA production by activating
SA5639, whilst at the same time inhibiting the competing
splice site, SA3358.
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DISCUSSION
SRp30c stimulated splicing of the late HPV-16 mRNAs,
thereby promoting production of the spliced L1 mRNA. In
HPV-16-infected cells, levels of SRp30c may therefore
increase in response to differentiation, or factors that
antagonize SRp30c, such as ASF/SF2, may decrease. In the
latter case, it would be the relative levels of splicing factors
that determine the outcome of the splicing events, rather
than absolute levels of SRp30c (Fig. 7). We have shown
previously that ASF/SF2 levels decrease in terminally
differentiated cells and increase in high-grade cervical
lesions and cervical cancer (Fay et al., 2009). It would
therefore be of interest to compare levels of individual SR
proteins in individual cells with those of L1 protein levels
in HPV-16-infected squamous epithelium. However, we
are not aware of antibodies against SRp30c that work in
immunohistochemistry.
The adenovirus E4orf4 protein decreases the phosphoryla-
tion of SR proteins in adenovirus-infected cells, thereby
inactivating these proteins and causing an alteration in
adenovirus alternative splicing that leads to induction of
adenovirus late gene expression (Kanopka et al., 1996,
1998). E4orf4 primarily binds ASF/SF2 (Estmer Nilsson
et al., 2001). Interestingly, adenovirus E4orf4 protein also
induces HPV-16 late gene expression (Somberg et al.,
2009), indicating that dephosphorylation of SR proteins
(or ASF/SF2, which is the primary partner of E4orf4) can
activate HPV-16 late gene expression. Similarly to
adenovirus, vaccinia virus infection also causes dephos-
phorylation of SR proteins in infected cells (Huang et al.,
2002). We have shown that SR proteins decrease in
abundance as cervical epithelial cells differentiate (Fay
et al., 2009), perhaps inducing HPV-16 late gene expression
in a manner similar to the inactivation of SR proteins by
dephosphorylation by adenovirus E4orf4. Whether down-
regulation of expression of SR proteins in differentiating
cervical epithelium alters the relative ratios of active SR
proteins in the infected cells, or whether SRp30c is
unaffected or increases in abundance in differentiated cells,
remains to be investigated.
High levels of SRp30c resulted in more L1i mRNAs at the
expense of the L1 mRNAs. As the only difference between
Fig. 5. (a) Schematic representation of subgenomic HPV-16 expression plasmids pBSplice and pBSpliceM (Somberg et al.,
2008). Mut indicates a number of nucleotide substitutions that inactivate splicing silencers downstream of SA5639 in plasmid
pBSpliceM. mRNAs that may be produced by the plasmids are indicated. Deletion mutants pBSpM3703–4530, pBSpM4288–
4530, pMT1SD and pMT3 are indicated. Numbers represent nucleotide positions of splice sites, poly(A) signals or borders of
deletions and refer to the HPV-16R sequence (Baker & Calef, 1997). The position of the L1 probe is indicated. (b–d) Northern
blots of cytoplasmic RNA extracted from HeLa cells transfected with the indicated plasmids in the absence or presence of
SRp30c. Blots were probed with the L1 or GAPDH probes. The positions of the L1 and GAPDH mRNAs and 18S and 28S
rRNAs are indicated. Note that in (d), the sizes of the bands differ as a result of the deletions.
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these two mRNAs was that L1i mRNAs lack the 275 nt
exon between SA3358 and SD3632, both L1 mRNAs should
be translated efficiently into L1 protein. In addition, both
L1 and L1i mRNAs have been observed in HPV-16-infected
cells (Baker & Calef, 1997; Milligan et al., 2007). The role of
SRp30c during HPV-16 infection may therefore be to
regulate HPV-16 late mRNA splicing and to determine the
ratio between L2 and L1/L1i mRNAs.
Overexpression of SRp30c has been shown to cause
redistribution of Y box-binding protein 1 (YB-1) into the
nucleus, presumably allowing YB-1 to regulate mRNA
splicing and/or transcription (Raffetseder et al., 2003).
Interestingly, YB-1 also interacts with hnRNP K and we
have previously reported that hnRNP K binds directly to
HPV-16 late mRNAs, immediately upstream of late 39-
splice site SA5639 (between SD3632 and SA5639) (Collier
et al., 1998). Other investigators have found SRp30c and
poly(C)-binding protein (PCBP; also known as hnRNP E)
present in the same RNA–protein complex that was formed
on the 39UTR of the human preprorenin mRNA (Skalweit
et al., 2003). We have shown previously that PCBP,
Fig. 6. (a) Schematic representation of the subgenomic HPV-16 expression plasmids pBELT9, pOPSD, pT9, pOPSDM and
pBELM (Rush et al., 2005; Zhao et al., 2004). Numbers represent nucleotide positions of splice sites, poly(A) signals or borders
of deletions. A subset of mRNAs that may be produced by the plasmids are indicated. The positions of the L1 probe and
RT-PCR primers 757s and L1A are shown. (b) Northern blot of cytoplasmic RNA extracted from HeLa cells transfected with
pBELM, pBELT9, pT9, pOPSD or pOPSDM in the absence or presence of SRp30c. The blot was hybridized to the L1 probe.
L1 and L1i mRNAs and 28S and 18S rRNAs are indicated. Lane 1 shows the results of a mock transfection. Detection of 28R
rRNA was used as a loading control. (c, d) RT-PCR with primers 757s and L1A on cDNA synthesized from cytoplasmic RNA
extracted from HeLa cells transfected with pBEL, pBELT9 or pOPSD (c), or pBELM, pT9 or pOPSDM (d), in the presence of
empty pBluecriptKS” vector (pKS) or SRp30c expression plasmid. The positions of bands representing L1 and L1i mRNAs are
indicated. Note that L1 mRNAs produced by pBELT9 or pT9 were smaller than those produced by pOPSD and pOPSDM due
to the 80 nt deletion in the E4-coding region. Detection of actin was used as a loading control.
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similarly to hnRNP K, binds specifically to the HPV-16 L2-
encoding region, immediately upstream of HPV-16 late 39-
splice site SA5639 (Collier et al., 1998). One may therefore
speculate that SRp30c could exert its enhancing effect on
HPV-16 late mRNA splicing at least partly through
proteins that bind to both YB-1 and HPV-16 mRNAs,
such as hnRNP K and PCBP.
METHODS
Plasmid constructs. The following plasmids have been described
previously: pBEL (Zhao et al., 2004), pBELM (Zhao et al., 2004),
pBearly (Zhao et al., 2005), pBSplice (Somberg et al., 2008),
pBSpliceM (Somberg et al., 2008), pMT3 (Somberg et al., 2008),
pBSpM4288–4530 (Somberg et al., 2008), pBELT9 (Rush et al., 2005),
pT9 (Rush et al., 2005), pOPSD (Rush et al., 2005), pOPSDM (Rush
et al., 2005), pT7wtexon4 (Somberg & Schwartz, 2010) and pMT1SD
(Somberg & Schwartz, 2010).
pBSpliceD3703-4530 was created by PCR-amplifying a sequence from
pBR-HPV-16 with primers E4S (Zhao et al., 2004) and M3A (see
Supplementary Table S1, available in JGV Online). The PCR fragment
was then subcloned into pCR2.1-TOPO, released with BssHII and
ApaI and subcloned into pBSpliceM. CMV-SRp30cDRS and CMV-
SRp55DRS were created by PCR-amplifying sequences from CMV-
SRp30c or CMV-SRp55 with primers 30cS and 30cDRSA, and SRp55S
and SRp55RRMAS, respectively (Supplementary Table S1). The PCR
fragments were then cleaved with BssHII and XhoI and subcloned into
pC0806 (Collier et al., 2002). pGST-SRp30c was created by PCR-
amplifying the sequence from pSRp30c with primers SRP30C-S and
SRP30C-AS (Supplementary Table S1). The PCR fragment was then
cleaved with BamHI and EcoRI and subcloned into pGEX-GST,
resulting in pGST-SRp30c.
pASF/SF2, pASFDRS, pSRp30c, pSRp55 and pAdE4orf4 were kind
gifts from Dr Göran Akusjärvi (IMBIM, Uppsala University, Sweden).
Transfection and cell culture. HeLa cells were cultured in Dulbecco’s
modified Eagle’s medium containing 10 % heat-inactivated FCS, 100 U
penicillin ml21 and 100 mg streptomycin ml21. Transfections were
carried out using Fugene 6 (Roche Molecular Biochemicals) according
to the manufacturer’s protocol, as described previously (Somberg et al.,
2008). All plasmids were transfected in a minimum of three independent
experiments with similar results.
RNA extraction, Northern blotting and radiolabelled DNA
probe synthesis. Cytoplasmic RNA was extracted using IsoB/NP-
40 buffer, as described previously (Wiklund et al., 2002). Northern
blotting was carried out by size separation of 10 mg cytoplasmic RNA
on 1.2 % agarose gels containing 2.2 M formaldehyde, followed by
transfer overnight to nitrocellulose filters subsequently hybridized
with an L1, E4 or GAPDH probe. The L1 probe was excised from
pBEL with BamHI and XhoI, whereas the E4 probe was generated by
PCR using primers E4S and K1 (Somberg & Schwartz, 2010). The
GAPDH probe was generated as described previously (Somberg &
Schwartz, 2010). DNA probes were radiolabelled with [a-32P]dCTP
using a Decaprime kit (Ambion).
RT-PCR. Cytoplasmic RNA (200 ng) was reverse-transcribed at
42 uC using SuperScript II and random hexamers according to the
manufacturer’s protocol (Invitrogen). The cDNA (2 ml) was amplified
in a 100 ml PCR using primers 757s and L1A or L1aM, as described
previously (Zhao et al., 2004). GAPDH cDNA was amplified as a
control using previously described primers (Johansson et al., 2005).
Purification of recombinant GST proteins and UV cross-linking.
Purification of recombinant GST-fusion proteins using glutathione–
Sepharose was performed as specified by the manufacturer (GE
Healthcare). Plasmid pT7wtexon4 was linearized with XbaI and
subjected to in vitro transcription with T7 RNA polymerase in the
presence of [a-32P]UTP. The RNA probe (105 c.p.m.) was UV cross-
linked to GST and GST-fusion proteins, as described previously
(Sokolowski et al., 1999).
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